Clinical trial NCT00005984: Cyclophosphamide and Filgrastim Followed By SCT in Patients With Chronic or Accelerated Phase Myelogenous Leukemia
Official title: Autologous Marrow Transplantation for Chronic Myelogenous Leukemia Using Stem Cells Obtained After In Vivo Cyclophosphamide/G-CSF Priming
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Leukemia
Keywords: chronic phase myelogenous leukemia
accelerated phase myelogenous leukemia
Lead sponsor: Masonic Cancer Center, University of Minnesota
Sponsor class: OTHER
First posted: 2003-01-27
Enrollment: 22
Sex: ALL
Maximum age (years): 70
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: RATIONALE: Giving colony-stimulating factors, such as G-CSF, and cyclophosphamide helps stem cells move from the patient's bone marrow to the blood so they can be collected and stored. Chemotherapy and radiation therapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy and radiation therapy.

PURPOSE: This phase II trial is studying how well cyclophosphamide plus filgrastim followed by stem cell transplant works in treating patients with chronic phase or accelerated phase chronic myelogenous leukemia.

Detailed description: OBJECTIVES:

* Assess the clinical outcomes, survival, and morbidity of patients with chronic or accelerated phase chronic myelogenous leukemia when treated with cyclophosphamide and filgrastim (G-CSF) followed by autologous peripheral blood stem cell transplantation.
* Determine whether priming with cyclophosphamide and filgrastim (G-CSF) increases the fraction of benign Philadelphia chromosome negative hematopoietic progenitors in peripheral blood stem cells (PBSC) and reduces the incidence of persistent or recurrent leukemia after autologous transplantation with mobilized PBSC in these patients.

OUTLINE: Patients receive priming therapy consisting of cyclophosphamide IV over 2 hours on day 1 and filgrastim (G-CSF) daily subcutaneously (SQ) starting on day 5 and continuing until completion of leukapheresis. Peripheral blood stem cells (PBSC) are collected between days 14-21.

Patients then receive preparative therapy for transplant consisting of cyclophosphamide IV over 2 hours on days -7 and -6 and total body irradiation twice a day on days -4 through -1. Patients receive the PBSC transplantation on day 0. Patients also receive G-CSF IV starting on day 0 and continuing until blood counts recover. Patients then receive interferon alfa SQ daily in the absence of unacceptable toxicity or disease progression.

Patients are followed at 3 weeks; then at 3, 6, 9, 12, and 18 months; and then annually for 5 years.

PROJECTED ACCRUAL: Not specified

Eligibility criteria: Inclusion Criteria:

* Histologically confirmed chronic or accelerated phase chronic myelogenous leukemia (CML)

  * Philadelphia chromosome positive OR
  * BCR/ABL rearrangement
* Ineligible or refused to participate in ongoing allogeneic marrow donor transplant protocols
* 70 and under
* Performance status:

  * Age 65-70 years:
  * Karnofsky 80-100%
  * Under 65 years:
  * Karnofsky 90-100%
* Renal:

  * Age 65-70 years:
  * Creatinine clearance greater than 60 mL/min (if creatinine at least 1.5 mg/dL)
  * Under 65 years:
  * Not specified
* Cardiovascular:

  * Age 65-70 years:
  * LVEF at least 45%
* Pulmonary:

  * Age 65-70 years:
  * If history of smoking or respiratory symptoms, spirometry and DLCO must be greater then 50% of predicted
* Normal organ function (excluding bone marrow)

Exclusion Criteria:

* Blast crisis or post blast crisis
* Severe fibrosis defined by bilateral trephine biopsies
* Splenomegaly (below umbilicus) that does not respond to chemotherapy and/or radiotherapy

Primary outcomes:
measure: Time to hemopoietic recovery after transplantation
measure: Detection of the Philadelphia chromosome or the BCR/ABL gene abnormality in post-transplantation marrow samples
Secondary outcomes:
measure: Time to initial hospital discharge
measure: Peritransplantation toxicity
measure: Quality of life at various time points
measure: Cause of death
Other outcomes:
Locations:
city: Minneapolis
country: United States
facility: University of Minnesota Cancer Center
state: Minnesota
Study officials:
affiliation: Masonic Cancer Center, University of Minnesota
name: Catherine M. Verfaillie, MD
role: STUDY_CHAIR
References: